Chemomab Therapeutics Ltd. Cost of Revenue
Chemomab Therapeutics Ltd. (CMMB) reported Cost of Revenue of $2.33 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-03-23
| Period end | Cost of Revenue 12 month |
|---|---|
| 2025-12-31 | $2.33M 20-F · filed 2026-03-23 |
| 2024-12-31 | $2.46M 20-F · filed 2026-03-23 |
| 2023-12-31 | $4.39M 20-F · filed 2026-03-23 |
| 2022-12-31 | $5.14M 20-F · filed 2025-04-04 |
| 2021-12-31 | $3.31M 20-F · filed 2024-03-28 |